Telix Strengthens Board with Two High-Profile Non-Executive Director Appointments

summarizeSummary

Telix Pharmaceuticals announced the appointment of Maria Rivas, MD (ex-Pfizer CMO) and William Jellison (ex-Stryker CFO) as Non-Executive Directors, enhancing the board's clinical, commercial, and financial expertise.

check_boxKey Events

• New Board Members Appointed

  Telix announced the appointment of Maria Rivas, MD, and William Jellison as Non-Executive Directors, effective May 11, 2026.

• Enhanced Clinical & Commercial Expertise

  Dr. Maria Rivas, former Chief Medical Officer at Pfizer, brings over 25 years of experience in late-stage clinical development, commercialization, and governance.

• Strengthened Financial Oversight

  Mr. William Jellison, former VP and CFO of Stryker Corporation, adds over 30 years of experience in corporate finance and audit committee leadership.

• Strategic Board Expansion

  These appointments are part of Telix's ongoing board expansion and succession planning, supporting its evolution as a dual-listed, global, commercial-stage biopharmaceutical company.

auto_awesomeAnalysis

These appointments significantly bolster Telix's board with deep expertise in critical areas. Dr. Rivas brings extensive experience in late-stage clinical development and commercialization from her tenure as Chief Medical Officer at Pfizer, while Mr. Jellison provides robust corporate finance and audit committee leadership from his background as CFO of Stryker. This strategic move, following another recent director appointment, aligns with Telix's growth as a dual-listed, global biopharmaceutical company, signaling a commitment to strong governance and operational oversight.